Rebootizer USA to sponsor kiteboarder Kris Kinn
WILTON, Conn. — Rebootizer USA on Tuesday signed Kris Kinn, professional kiteboarder and international team rider for Best Kiteboarding, to its team of sponsored athletes.
Kinn grew up on the shores of Lake Erie in Buffalo, N.Y. She began kiteboarding six years ago and now travels the world competing in national and international events.
Rebootizer sees the partnership with Kinn as an opportunity to increase both brand awareness and kiteboarding’s visibility, with a goal of having it be recognized as an Olympic sport, the company stated. "We are proud and excited to welcome Kris Kinn to the team of athletes we sponsor," stated Rebootizer CEO Catherine Brandt. "Rebootizer promotes health and wellness by integrating a regular detox regimen that naturally enhances the body’s detox and digestive functions, allowing it to perform at its peek physically."
Kris Kinn’s first appearance representing Rebootizer will be March 18 to 20 in Richmond, Va., where Rebootizer USA is partnering with “The Balancing Act,” a national women’s morning show on Lifetime television produced by O2 Media, for the second of five sponsorships of the "Balance Your Life" Road Tour with Southern Women’s Shows. The event will take place at the Richmond Raceway Complex.
"Rebootizer is an amazing product and I couldn’t be happier with my new partnership with this company," Kinn said. "With my professional athlete lifestyle, staying fit and healthy is my No. 1 priority.”
Rebootizer began its support of kiteboarding in 2010 by partnering with professional kiteboarder and Triple S champion Davey Blair.
NPA to China: Increase transparency, U.S. imports
WASHINGTON — The Natural Products Association on Wednesday outlined five key industry issues for the U.S. Department of Commerce and the Office of the United States Trade Representative for the U.S.-China Joint Commission on Commerce and Trade.
The NPA focused on removing barriers for trade to China with recommendations on increasing transparency, clarifying and reforming regulations, and enhancing export opportunities.
“Ranking fourth in sales behind the United States, Japan and Europe, China is a market of growing importance for dietary supplement makers and the natural products industry at large,” stated John Gay, NPA executive director and CEO. “NPA continues to play a constructive role with U.S. and Chinese officials to work toward the goal of increasing U.S. exports.”
NPA’s recommendations focused on five key areas:
Product registration: Reduce the time and cost of registering new and existing products with China’s State Food and Drug Administration;
Functional claims: Expand China’s list of approved functional claims and simplify the regulatory process;
Potency restrictions: Modify potency-level restrictions to conform to current dietary supplement research;
Dosage form: Clarify among regulators, custom agents and manufacturers the form in which dietary supplements may be sold in China; and
Gray market activity: Eliminate ambiguity and the restrictive nature of current regulations to encourage companies to follow the SFDA’s regulations.
For the complete copy of the NPA’s comments, go to NPAinfo.org/comments.
Asthma relief soon to revert to Rx-only indication
SILVER SPRING, Md. — The Food and Drug Administration on Wednesday announced that the only over-the-counter asthma inhaler sold in the United States no longer will be available as of Dec. 31 as part of an international agreement to stop the use of substances that damage the environment.
Armstrong Pharmaceuticals’ Primatene Mist (epinephrine) is approved by the FDA for the temporary relief of occasional symptoms of mild asthma. As part of the announcement, the FDA urged those who use Primatene Mist to see a healthcare professional soon to switch to another asthma medicine.
Primatene Mist inhalers are being discontinued because they use chlorofluorocarbons, or CFCs, as a propellant to move the medicine out of the inhaler so patients can breathe the medicine into their lungs.
“There are many other safe and effective medications to treat the symptoms of asthma,” stated Badrul Chowdhury, director of the FDA’s Division of Pulmonary, Allergy and Rheumatology Products. But you need to find out if you really have asthma — not just pick another over-the-counter medicine, Chowdhury added. “If you have breathing problems but have not been diagnosed by a healthcare professional, it’s important to see one. Not all breathing problems are asthma, so you need to get an accurate diagnosis and the proper medicine.”
Many manufacturers have changed their inhalers to replace CFCs with an environmentally friendly propellant called hydrofluoroalkane, or HFA. There currently is no HFA version of the Primatene Mist inhaler.